Usmarapride

  1. Home
  2. Wiki

Usmarapride
Clinical data
Other namesSUVN-D4010; SUVN-D-4010
Routes of
administration		Oral[1]
Drug classSerotonin 5-HT4 receptor agonist
ATC code
  • None
Identifiers
  • 2-[1-(3-methoxypropyl)piperidin-4-yl]-5-(1-propan-2-ylindazol-3-yl)-1,3,4-oxadiazole
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC21H29N5O2
Molar mass383.496 g·mol−1
3D model (JSmol)
  • CC(C)N1C2=CC=CC=C2C(=N1)C3=NN=C(O3)C4CCN(CC4)CCCOC
  • InChI=1S/C21H29N5O2/c1-15(2)26-18-8-5-4-7-17(18)19(24-26)21-23-22-20(28-21)16-9-12-25(13-10-16)11-6-14-27-3/h4-5,7-8,15-16H,6,9-14H2,1-3H3
  • Key:DWTFBJGTRBMHPG-UHFFFAOYSA-N

Usmarapride (INNTooltip International Nonproprietary Name; developmental code name SUVN-D4010) is a serotonin 5-HT4 receptor agonist which is or was under development for the treatment of cognitive deficits in Alzheimer's disease and schizophrenia.[1][2][3] It is taken orally.[1]

Pharmacology

[edit]

The drug is a potent and selective partial agonist of the serotonin 5-HT4 receptor.[2][3] It is highly selective against the serotonin 5-HT3 receptor and other closely related receptors.[2] The drug shows cognition- and memory-enhancing effects, neuroprotective effects, and antidepressant-like effects in preclinical research.[2][3][4] Its pharmacokinetics and pharmacodynamics have been evaluated in humans.[2][5] In terms of chemical structure, the drug is an indazole derivative.[6]

Development

[edit]

Usmarapride is under development by Suven Life Sciences.[1] As of September 2023, no recent development has been reported for treatment of Alzheimer's disease and schizophrenia.[1] The drug has reached phase 1 clinical trials for both of these indications.[1]

References

[edit]
  1. ^ a b c d e f "Usmarapride - Suven Life Sciences". AdisInsight. 28 September 2023. Retrieved 1 October 2025.
  2. ^ a b c d e Nirogi R, Mohammed AR, Shinde AK, Gagginapally SR, Kancharla DM, Ravella SR, et al. (August 2021). "Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease". J Med Chem. 64 (15): 10641–10665. doi:10.1021/acs.jmedchem.1c00703. PMID 34251799.
  3. ^ a b c Nirogi R, Grandhi VR, Medapati R, Ganuga N, Abraham R, Thentu JB, et al. (May 2023). "Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling". Eur J Pharmacol. 947 175625. doi:10.1016/j.ejphar.2023.175625. PMID 36997046.
  4. ^ Abraham R, Subramanian R, Rasheed MA, Ravella SR, Malleshwari D, Thentu JB, et al. (2022). "Usmarapride Oxalate (SUVN-D4010): A Serotonin-4 Receptor Partial Agonist for the Treatment of Cognitive Disorders". Alzheimer's & Dementia. 18 (S10) e062167. doi:10.1002/alz.062167. ISSN 1552-5260. Retrieved 1 October 2025.
  5. ^ Nirogi R, Bhyrapuneni G, Muddana NR, Goyal VK, Pandey SK, Mohammed AR, et al. (May 2021). "First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects". Clin Drug Investig. 41 (5): 469–482. doi:10.1007/s40261-021-01027-4. PMID 33788154.
  6. ^ Dallemagne P, Rochais C (July 2021). "5-HT4R modulators: a patent landscape". Pharm Pat Anal. 10 (4): 179–181. doi:10.4155/ppa-2021-0017. PMID 34365797.



Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.